Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorViome
About this trial
This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.
Eligibility criteria
Qualifiers
Signed and dated informed consent form and medical release prior to any trial-specific procedures are performed
Females and males aged 18 years or older
Able to speak and read English
HbA1c between 5.7-8.9% (inclusive), tested within the past 30 days
Disqualifiers
Antibiotic use within one month of the GI test
Gestation within previous 6 month
Current (or previous) use of medications that increase insulin (sulfonylureas, such as glimepiride, glipizide, glyburide, etc.)
Current (or previous) use of exogenous insulin (such as Tresiba, Lantus, Toujeo, Levemir, Humalog, Novolog, Apidra, Fiasp, etc.)
Trial design
Treatments tested in this trial
- Viome's Precision Nutrition Program (VPNP)
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov